Biohaven - International Biopharmaceutical Industry

news

Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs

Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a big bet on it...

13 May 2022 news Biohaven | Drugs

Continue Reading →

news

Biohaven to seek FDA approval for second migraine drug after study success

While a smaller biotech company, Biohaven has succeeded in a market led by large pharmaceutical firms like Lilly, AbbVie and, in the preventive treatment setting, Amg...

10 December 2021 news ABBVIE | Amgen

Continue Reading →

news

Pfizer buys into Biohaven’s fast-selling migraine medicine

Faced with breaking into markets led by larger companies, Biohaven turned to celebrity endorsements, Tiktok and racecar advertising to aggressively sell Nurtec ODT. I...

15 November 2021 news Biohaven | migraine

Continue Reading →

news

Biohaven’s pipeline takes a hit as drug for rare neurological disease falls short in trial

Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales that we...